Does Legalizing Cannabis Increase Adolescent Use? This Expert Found Mixed Results.
Contrary to expectation, a major study found that weed use among minors was lower in states where the drug was legal.
Contrary to expectation, a major study found that weed use among minors was lower in states where the drug was legal.
Experts say the new feature may offer dubious advice in response to personal health queries.
Experts say the new feature may offer dubious advice in response to personal health queries.
ASCO 2024 DV-001 trial, disitamab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC) expressing HER2, Monomethyl…
ASCO 2024 phase III STELLAR-304 trial, combination of zanzalintinib (XL092) plus nivolumab in patients with non-clear cell renal cell carcinoma (nccRCC), tyrosine kinase inhibitor (TKI)…
Some people who wanted to improve their lives and careers through coaching found themselves trapped in what they described as a pyramid scheme.
Micah Ostrowski Huntsman Cancer Institute, University of Utah, Salt Lake City, UT Micah Ostrowski, Yeonjung Jo, Georges Gebrael, Chadi Hage Chehade, Arshit Narang, Gliceida Galarza…
ASCO 2024 post hoc analysis of ARASENS, metastatic hormone-sensitive prostate cancer (mHSPC), darolutamide, metastatic castration-resistant prostate cancer (mCRPC), ADT + docetaxel, abiraterone, enzalutamide, cabazitaxel, docetaxel,…
ASCO 2024 artificial intelligence-based digital histology classifier for prostate cancer recurrence and metastasis risk prediction, PATHOMIQ_PRAD, PATHOMIQ_PRAD score.
ASCO 2024, prostate cancer, COBRA study, 64Cu-SAR-bisPSMA, Assessment of Safety and Efficacy of 64Cu-SAR-bisPSMA in Patients with Biochemical Recurrence of Prostate Cancer Following Definitive Therapy.
ASCO 2024 trial design of CELC-G-201, gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC), PAM signaling, PI3K-mTOR inhibitor.